373 related articles for article (PubMed ID: 25134829)
1. Autophagy as a modulator and target in prostate cancer.
Farrow JM; Yang JC; Evans CP
Nat Rev Urol; 2014 Sep; 11(9):508-16. PubMed ID: 25134829
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
3. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
Nguyen HG; Yang JC; Kung HJ; Shi XB; Tilki D; Lara PN; DeVere White RW; Gao AC; Evans CP
Oncogene; 2014 Sep; 33(36):4521-30. PubMed ID: 24662833
[TBL] [Abstract][Full Text] [Related]
4. Targeting tyrosine kinases and autophagy in prostate cancer.
Kung HJ
Horm Cancer; 2011 Feb; 2(1):38-46. PubMed ID: 21350583
[TBL] [Abstract][Full Text] [Related]
5. Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells.
Kaini RR; Hu CA
Biochem Biophys Res Commun; 2012 Aug; 425(2):150-6. PubMed ID: 22819840
[TBL] [Abstract][Full Text] [Related]
6. Autophagy in prostate cancer and androgen suppression therapy.
Ziparo E; Petrungaro S; Marini ES; Starace D; Conti S; Facchiano A; Filippini A; Giampietri C
Int J Mol Sci; 2013 Jun; 14(6):12090-106. PubMed ID: 23743823
[TBL] [Abstract][Full Text] [Related]
7. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.
Ashrafizadeh M; Paskeh MDA; Mirzaei S; Gholami MH; Zarrabi A; Hashemi F; Hushmandi K; Hashemi M; Nabavi N; Crea F; Ren J; Klionsky DJ; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Mar; 41(1):105. PubMed ID: 35317831
[TBL] [Abstract][Full Text] [Related]
8. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model.
Draz H; Goldberg AA; Tomlinson Guns ES; Fazli L; Safe S; Sanderson JT
Invest New Drugs; 2018 Aug; 36(4):718-725. PubMed ID: 29607466
[TBL] [Abstract][Full Text] [Related]
10. Autophagy modulation: a target for cancer treatment development.
Duffy A; Le J; Sausville E; Emadi A
Cancer Chemother Pharmacol; 2015 Mar; 75(3):439-47. PubMed ID: 25422156
[TBL] [Abstract][Full Text] [Related]
11. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
Kaini RR; Sillerud LO; Zhaorigetu S; Hu CA
Prostate; 2012 Sep; 72(13):1412-22. PubMed ID: 22294520
[TBL] [Abstract][Full Text] [Related]
12. Effect of dual inhibition of apoptosis and autophagy in prostate cancer.
Saleem A; Dvorzhinski D; Santanam U; Mathew R; Bray K; Stein M; White E; DiPaola RS
Prostate; 2012 Sep; 72(12):1374-81. PubMed ID: 22241682
[TBL] [Abstract][Full Text] [Related]
13. Autophagy therapeutics: preclinical basis and initial clinical studies.
Zhan L; Li J; Wei B
Cancer Chemother Pharmacol; 2018 Dec; 82(6):923-934. PubMed ID: 30225602
[TBL] [Abstract][Full Text] [Related]
14. Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition.
Schmukler E; Shai B; Ehrlich M; Pinkas-Kramarski R
PLoS One; 2012; 7(5):e36828. PubMed ID: 22606295
[TBL] [Abstract][Full Text] [Related]
15. p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
Wang L; Kim D; Wise JTF; Shi X; Zhang Z; DiPaola RS
Prostate; 2018 Apr; 78(5):390-400. PubMed ID: 29368435
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy.
DiPaola RS; Dvorzhinski D; Thalasila A; Garikapaty V; Doram D; May M; Bray K; Mathew R; Beaudoin B; Karp C; Stein M; Foran DJ; White E
Prostate; 2008 Dec; 68(16):1743-52. PubMed ID: 18767033
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
[TBL] [Abstract][Full Text] [Related]
18. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy addiction in cancer.
Mancias JD; Kimmelman AC
Oncotarget; 2011 Dec; 2(12):1302-6. PubMed ID: 22185891
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy.
Vyas AR; Hahm ER; Arlotti JA; Watkins S; Stolz DB; Desai D; Amin S; Singh SV
Cancer Res; 2013 Oct; 73(19):5985-95. PubMed ID: 23921360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
